Trial · NCT00699972
Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
NCT00699972, Phase 3, Completed, Eisai Inc.; results first posted 2013-02-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures. Trials, record NCT00699972. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00699972
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
- NCT number
- NCT00699972
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 390 participants, actual
- Lead sponsor
- Eisai Inc.
- Conditions
- Refractory Partial Seizures
- Interventions
- E2007 (perampanel), E2007 (perampanel), Placebo
- First posted
- 2008-06-18
- Last updated
- 2020-01-10
- Results first posted
- 2013-02-05
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | Baseline (Pre-randomization) through Week 19 | Seizure frequency per 28 days was derived from the information recorded in the subject diaries. |
| Secondary | Percentage of Participants Who Were Responders | Baseline (Pre-randomization) through Week 19 | A responder was a participant who had a 50 percent or greater reduction in seizure frequency per 28 days from the Pre-randomization phase. |
| Secondary | Percent Change in the 28-day Complex Partial Plus Secondarily Generalized Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | Baseline (Pre-randomization) through Week 19 | Percent Change in the Seizure frequency per 28 days was derived from the information recorded in the subject diaries. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | Baseline (Pre-randomization) through Week 19 | Full Intent-to-Treat (ITT) Analysis Set included all participants who were randomized to study drug, received study drug, and had any seizure frequency data during the Double-blind Phase. | Percent Change in seizure frequency | MEDIAN |
| SECONDARY | Percentage of Participants Who Were Responders | Baseline (Pre-randomization) through Week 19 | Full ITT Analysis Set; Last Observation Carried Forward (LOCF) | Percentage of Participants | NUMBER |
| SECONDARY | Percent Change in the 28-day Complex Partial Plus Secondarily Generalized Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | Baseline (Pre-randomization) through Week 19 | Full ITT Analysis Set | Percent Change | MEDIAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | Placebo | -20.95 | Full Range -100.0 to 397.5 | Percent Change in seizure frequency | |
| Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | Perampanel 8mg | -26.34 | Full Range -100.0 to 150.7 | Percent Change in seizure frequency | |
| Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | Perampanel 12mg | -34.49 | Full Range -100.0 to 659.7 | Percent Change in seizure frequency | |
| Percentage of Participants Who Were Responders | Placebo | Yes (Responder) | 26.4 | Percentage of Participants | |
| Percentage of Participants Who Were Responders | Perampanel 8mg | Yes (Responder) | 37.6 | Percentage of Participants | |
| Percentage of Participants Who Were Responders | Perampanel 12mg | Yes (Responder) | 36.1 | Percentage of Participants | |
| Percentage of Participants Who Were Responders | Placebo | No (Non-Responder) | 73.6 | Percentage of Participants | |
| Percentage of Participants Who Were Responders | Perampanel 8mg | No (Non-Responder) | 62.4 | Percentage of Participants | |
| Percentage of Participants Who Were Responders | Perampanel 12mg | No (Non-Responder) | 63.9 | Percentage of Participants | |
| Percent Change in the 28-day Complex Partial Plus Secondarily Generalized Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | Placebo | -17.88 | Full Range -100.0 to 653.5 | Percent Change |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 122 | |
| Overall Study | STARTED | Perampanel 8mg | 133 | |
| Overall Study | STARTED | Perampanel 12mg | 135 | |
| Overall Study | COMPLETED | Placebo | 106 | |
| Overall Study | COMPLETED | Perampanel 8mg | 114 | |
| Overall Study | COMPLETED | Perampanel 12mg | 100 | |
| Overall Study | NOT COMPLETED | Placebo | 16 | |
| Overall Study | NOT COMPLETED | Perampanel 8mg | 19 | |
| Overall Study | NOT COMPLETED | Perampanel 12mg | 35 |
Source ClinicalTrials.gov
Adverse events144
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Vertigo | Ear and labyrinth disorders | Placebo | 0 | 121 | |
| other | Vertigo | Ear and labyrinth disorders | Perampanel 8mg | 4 | 133 | |
| other | Vertigo | Ear and labyrinth disorders | Perampanel 12mg | 7 | 134 | |
| other | Diarrhoea | Gastrointestinal disorders | Placebo | 8 | 121 | |
| other | Diarrhoea | Gastrointestinal disorders | Perampanel 8mg | 9 | 133 | |
| other | Diarrhoea | Gastrointestinal disorders | Perampanel 12mg | 6 | 134 | |
| other | Nausea | Gastrointestinal disorders | Placebo | 8 | 121 | |
| other | Nausea | Gastrointestinal disorders | Perampanel 8mg | 9 | 133 | |
| other | Nausea | Gastrointestinal disorders | Perampanel 12mg | 8 | 134 | |
| other | Vomiting | Gastrointestinal disorders | Placebo | 5 | 121 |
1 to 10 of 144Source ClinicalTrials.gov
See all 144 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | 0 | 121 |
| Total, all-cause mortality | Perampanel 8mg | 0 | 133 |
| Total, all-cause mortality | Perampanel 12mg | 0 | 134 |
| Total, other adverse events | Placebo | 71 | 121 |
| Total, other adverse events | Perampanel 8mg | 101 | 133 |
| Total, other adverse events | Perampanel 12mg | 98 | 134 |
| Total, serious adverse events | Placebo | 6 | 121 |
| Total, serious adverse events | Perampanel 8mg | 8 | 133 |
| Total, serious adverse events | Perampanel 12mg | 9 | 134 |
Source ClinicalTrials.gov
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00699972
GET https://conductscience.org/api/trials/v1/NCT00699972/events?page=2